ATTR Cardiac Amyloidosis in Older Adults: The Diagnosis That Was Hiding the Whole Time
You're in your seventies. The breathing has been getting harder over the past year, especially up the stairs and lying flat at night. Your ankles puff up by dinner. The cardiologist did an echocardiogram and the walls of your heart looked thicker than they should be. The blood pressure has actually been on the low side, which doesn't fit. Your hands tingle and your palms feel weak gripping a coffee cup, and a few years back you had carpal tunnel surgery on both hands. Maybe a back surgeon worked on your lumbar spine for stenosis. Somewhere along the way one of your biceps tendons popped while you were lifting a grocery bag. None of that seemed connected to the heart. Now your cardiologist is saying the word "amyloid" and asking if you'd be willing to do a special scan, and you want to know what's going on.
What you're describing is the classic story of a condition called wild-type ATTR cardiac amyloidosis. The short version: a protein your liver makes called transthyretin starts behaving badly with age. It folds wrong and starts piling up in your tissues, including the muscle of your heart. The hands and the spine usually announce the problem long before the heart does. For decades this disease was thought to be rare, found mainly on autopsy, and not worth chasing in clinic because we couldn't do anything about it. All three of those assumptions turned out to be wrong.
There's a broader overview of ATTR amyloidosis on this site if you want the full landscape. This article focuses on the older-adult version, sometimes called senile cardiac amyloid, that gets missed most often in patients over seventy with heart failure and a preserved pumping function.
Why ATTR in Older Adults Gets Missed
The first reason is simple. The symptoms look like ordinary heart failure in an older person. Shortness of breath, swelling in the legs, fatigue, a slow drop in exercise tolerance. The working diagnosis becomes heart failure with preserved ejection fraction, often shortened to HFpEF. The pumping function on the echocardiogram looks normal or near normal, so people get told the heart "squeezes fine, it just doesn't relax well." That can be true. It can also be hiding amyloid. When researchers systematically test older HFpEF patients with the right imaging, around 13 to 17 percent turn out to have wild-type ATTR amyloid underneath. Roughly one in seven older adults walking around with HFpEF has an amyloid story being missed. Men are affected far more often than women, and the chance climbs sharply into the late seventies and eighties.
The second reason is that the disease wears costumes. Before the heart symptoms hit, the protein has often been depositing for ten or fifteen years in places that don't connect in most doctors' minds: the wrist (carpal tunnel), the lumbar spine (a kind of spinal stenosis), and the shoulder (biceps tendon ruptures). Those problems get treated by hand surgeons and back surgeons and orthopedists, and nobody is thinking about the heart. By the time the heart announces itself, the orthopedic history is years old and rarely gets brought up.
The third reason is older. For a long time we had no treatment, so there was no urgency to chase a difficult diagnosis. That isn't true anymore. Two oral medications can now slow the disease, and a newer class of injectable drugs can shut down production of the bad protein. Diagnosing this matters now in a way it didn't ten years ago.
The Hand Surgery Clue, and the Spine Clue
If a patient comes into my clinic with HFpEF and the hint of thick heart walls, the first question I want answered is whether they've had carpal tunnel surgery, especially on both hands. Bilateral carpal tunnel release five to ten years before heart symptoms is one of the loudest red flags we have. The protein deposits in the soft tissue around the median nerve at the wrist, the carpal tunnel narrows, and the nerve gets pinched. Decades of cumulative deposition show up as numbness and weakness in the hands long before the heart muscle is stiff enough to bother you. Studies of patients undergoing carpal tunnel surgery in their seventies have found amyloid in the wrist tissue in roughly one in three cases when investigators look for it. Many of those patients later develop cardiac amyloidosis.
The lumbar spine version of the same story is lumbar spinal stenosis. The yellow ligament running along the back of the spinal canal can thicken with amyloid deposition, narrowing the canal and pinching nerves. Patients describe pain and numbness when they walk that gets better when they sit or lean forward over a grocery cart. Many older adults have lumbar stenosis from plain wear and tear; what raises a flag is when stenosis shows up alongside thick heart walls, carpal tunnel, or unexplained heart failure in the same person.
Two more clues round out the orthopedic picture. A spontaneous rupture of the biceps tendon, the so-called Popeye sign in an older man with no clear injury, has a real association with ATTR. So does a rotator cuff tear out of proportion to the activity. None of these by themselves prove anything. Together with the heart picture, they form a pattern. The reason I push on this history in clinic is that older patients often don't volunteer it. They had carpal tunnel surgery a decade ago, the hand surgeon never said the word amyloid, and they moved on. When I ask, the story comes out and the picture changes.
What the Echo and EKG Show
The echocardiogram is usually where the suspicion starts. Several findings together raise the question. The walls of the left ventricle look thick in a patient who has never had high blood pressure, which is odd because blood pressure normally drives wall thickening. The right ventricle and the atrial walls can look thick too, unusual for ordinary hypertrophic cardiomyopathy. The texture of the muscle can have a speckled, sparkly appearance, sometimes described as "granular sparkling." Amyloid hearts develop a stiff filling pattern called restrictive physiology: the chambers don't relax well, pressures rise, and the atria enlarge to compensate.
The most useful echo clue in modern practice comes from a measurement called global longitudinal strain, which tracks how much different parts of the heart muscle squeeze and shorten with each beat. In ATTR amyloid, the bottom and middle of the ventricle squeeze poorly while the very tip of the heart still squeezes almost normally. The tip of the heart squeezes more than the rest, an unusual pattern that's been called the "bullseye" appearance on the color map. When that pattern shows up in an older patient with thick walls and HFpEF, the suspicion for amyloid jumps.
The EKG adds its own quiet clue. You'd expect a thick-walled heart to produce big voltages on the EKG. Amyloid does the opposite. The heart muscle is infiltrated rather than truly hypertrophied, so the voltages on the limb leads are often low, sometimes strikingly so. That mismatch between thick walls on echo and small voltages on EKG is one of the cleanest signals we have. Some patients also show a pseudoinfarct pattern that mimics an old heart attack. Conduction can be slow, and a fair number of patients eventually need a pacemaker. A heart MRI, when ordered, can show a pattern of late gadolinium enhancement that's almost diagnostic of cardiac amyloid.
The Pyrophosphate Scan: A Near-Painless Test That Finds It
For decades the only way to confirm cardiac amyloid was a heart muscle biopsy. That's a real procedure with real risks. One of the largest changes in this field has been the realization that a nuclear medicine scan called a technetium pyrophosphate scan, often shortened to a PYP scan, can diagnose ATTR cardiac amyloid with very high accuracy in the right setting, no biopsy needed.
Here's how it works in plain terms. The technician injects a small amount of a mildly radioactive tracer through an IV. The tracer happens to bind to ATTR amyloid deposits in the heart muscle. A few hours later you lie on a scanner for about twenty minutes. If your heart muscle picks up the tracer at a high level compared to your ribs, that's a positive scan. The radiation dose is comparable to a regular bone scan, the test is painless apart from the IV, and there's nothing to recover from afterward.
The catch is that the PYP scan only confirms ATTR amyloid after we've ruled out a different and rarer kind of amyloid called AL amyloid, which comes from the bone marrow rather than the liver. AL amyloid is a faster, more dangerous disease that requires very different treatment, often involving an oncologist and chemotherapy. If we treat the wrong kind, we miss the boat. Before the PYP scan or alongside it, every patient gets blood and urine tests looking for the protein fingerprints of AL amyloid: a serum free light chain assay and serum and urine protein electrophoresis with immunofixation. If those tests are clean and the PYP scan is positive, the diagnosis of ATTR is locked in without a biopsy.
If the AL workup turns up something abnormal, we slow down. We send the patient to a hematologist, and a biopsy of the heart or another tissue is needed to sort it out. Mistaking AL for ATTR is one of the few real ways to harm a patient with this workup, which is why the order of testing matters so much.
How Wild-Type ATTR Differs From Hereditary ATTR
The protein that's misbehaving is the same in both: transthyretin. The difference is whether the gene that codes for that protein is normal or carries a mutation.
In wild-type ATTR, the gene is normal. The protein simply becomes less stable with age, comes apart at its joints, refolds wrong, and starts piling up. This is the form that affects mostly older men, often diagnosed in the late seventies and eighties, and it shows up as the cardiac and orthopedic story I've described.
In hereditary ATTR, the gene carries a single-letter mutation that makes the protein unstable earlier in life. Different mutations produce different patterns. Some make a heart-dominant disease that looks like wild-type but starts younger. Others make a nerve-dominant disease that causes painful neuropathy in the feet and hands, autonomic problems like dizziness on standing, and only later affects the heart. The Val122Ile variant, for example, is found in roughly 3 to 4 percent of African American adults and predisposes to a later-onset heart amyloid that often gets missed.
Genetic testing matters for two reasons. First, hereditary ATTR has implications for the patient's children and siblings, who may want testing themselves. Second, treatment choices can differ. When a PYP scan and lab workup confirm ATTR cardiac amyloid in an older patient, we send a blood sample for TTR gene sequencing. About 90 percent of older patients turn out to have wild-type disease and the gene comes back normal. The remaining 10 percent or so have a mutation, and that finding rewrites the family conversation.
Why an Aortic Valve Specialist Might Suspect Amyloid
A growing chapter of this story involves low-flow, low-gradient aortic stenosis. Aortic stenosis is a tightening of the heart's outflow valve, common in older adults. Most patients with severe aortic stenosis have a strong, fast jet of blood coming through the narrowed valve. Some older patients have a tightened valve with a weaker jet and a lower-than-expected gradient. That used to be chalked up to a weak heart. We now recognize that a meaningful fraction of those low-flow, low-gradient cases have ATTR amyloid as a co-pilot, stiffening the muscle and reducing how much blood the ventricle can push through any valve.
Studies in patients undergoing transcatheter aortic valve replacement, the procedure many older adults now have for severe aortic stenosis, have found ATTR amyloid in roughly one in seven of these patients. Among those with the low-flow, low-gradient pattern in particular, the proportion is higher. The valve still needs to be fixed in many of these patients, and recognizing the amyloid changes the prognosis conversation and may justify starting amyloid therapy. If your aortic valve is tight and the picture doesn't quite fit the textbook, ask whether amyloid has been considered.
Treatments That Actually Work Now
For most of my career, ATTR cardiac amyloidosis was a diagnosis I had to deliver alongside the news that there wasn't much we could do. That changed in 2018 with the approval of tafamidis, sold under the brand name Vyndamax or Vyndaqel. Tafamidis works by stabilizing the transthyretin protein. The protein normally floats around in the bloodstream as a four-piece assembly, and before it can pile up in tissues it has to come apart. Tafamidis grips the assembly and holds it together, so the protein keeps doing its normal job and stops shedding into amyloid deposits.
The trial that brought tafamidis to market enrolled 441 patients with ATTR cardiac amyloidosis, both wild-type and hereditary, and randomized them to drug or placebo for 30 months. Patients on tafamidis lived longer, were hospitalized for heart failure less often, and walked farther on a six-minute walk test than patients on placebo. The benefit was clearer in patients who started treatment earlier in their disease course, which is the main reason early diagnosis matters so much. The drug is well tolerated. Most patients have no day-to-day side effects. The price tag has been the harder pill to swallow. Tafamidis runs into the hundreds of thousands of dollars a year at list price, and most patients access it through a combination of insurance authorization and the manufacturer's patient assistance program.
In late 2024 the FDA approved a second oral stabilizer called acoramidis, sold as Attruby. The trial that supported its approval enrolled about 600 patients with ATTR cardiomyopathy and randomized them to acoramidis or placebo for 30 months. The drug reduced a combined measure of death and cardiovascular hospitalization, with the benefit clearest in the second year of treatment. Acoramidis binds transthyretin more completely than tafamidis at the doses used. Whether it produces a meaningfully better clinical result in head-to-head terms is still being worked out. For now we have two stabilizers with broadly similar mechanisms, both supported by good data, and the choice often comes down to insurance coverage and side effect profile.
A third class of drugs takes a different approach. Instead of stabilizing the protein, these medications shut off its production at the source. The liver makes transthyretin from a genetic instruction, and the newer drugs, called silencers, intercept that instruction so the liver makes much less of the protein. Patisiran is given as an IV infusion every three weeks. Vutrisiran is a subcutaneous injection every three months. Eplontersen is a monthly subcutaneous injection. All three were first approved for the nerve form of hereditary ATTR, where the trial data showed clear improvement in nerve symptoms and quality of life. Vutrisiran now has 2024 data showing a benefit in patients with ATTR cardiomyopathy as well. These silencer drugs are being considered alongside the stabilizers, especially in patients with mixed nerve and heart disease or in those who progress on a stabilizer alone.
Beyond the amyloid-specific drugs, the heart failure piece still needs ordinary heart failure care. Diuretics keep the lungs and ankles from filling with fluid. Salt restriction matters. The standard heart failure pills like beta blockers and renin-angiotensin blockers have to be used carefully in amyloid because the heart depends on a fast rate and an intact blood pressure to compensate for stiff filling. We often end up using lower doses than we would in routine HFpEF. SGLT2 inhibitors are increasingly added to the regimen. Amyloid hearts have a higher rate of atrial fibrillation and a higher rate of clot formation in the atrium at sinus rhythm, so the threshold to start a blood thinner is lower than in non-amyloid heart failure.
Prognosis and What to Expect
The honest answer is that prognosis depends on how far along the disease is when we find it. Two laboratory values are the workhorses of staging: the NT-proBNP level, a marker of heart strain, and the troponin level, a marker of low-level heart muscle injury. Patients with both values in the lower range have the best prognosis. Patients with both in the higher range have a much shorter median survival on treatment. The Mayo and UK staging schemes sort patients into three or four groups with median survivals ranging from over five years in the earliest stage to under two years in the most advanced.
Tafamidis trial data showed that patients in the earliest stages had the largest survival benefit from treatment, on the order of doubling event-free survival over a few years. Catching the disease before it has progressed to the most advanced stage changes the trajectory in a real way. That's the central reason for working hard on the diagnosis early.
Day-to-day, the disease progresses slowly. Most patients with wild-type ATTR have a slow tightening of exercise tolerance over several years rather than a sudden collapse. Episodes of fluid overload come and go, often triggered by a salty meal, a missed diuretic dose, or a cold. Atrial fibrillation is common and may require rhythm or rate control along with anticoagulation. Some patients develop slow conduction in the heart and need a pacemaker. The advanced stages bring more frequent hospitalizations and progressive limitation. Treatment doesn't reverse the disease, and it does meaningfully slow it.
When to Refer to a Specialty Amyloid Center
A general cardiologist with experience in heart failure can manage most patients with ATTR cardiac amyloidosis. Diagnosis, staging, prescribing of tafamidis or acoramidis, and heart failure care all fit within the scope of a strong general practice. There are situations where referral to a dedicated amyloid center pays off.
Hereditary disease, in younger patients or in those with mixed nerve and heart involvement, deserves the perspective of a center that sees high volumes of these cases. Genetic counseling for family members is best handled there. The silencer drugs, with their more complex administration, are often easier to access through a coordinated amyloid program. Patients who progress despite treatment, who develop advanced conduction problems, or who become candidates for a heart transplant benefit from amyloid-specific expertise.
When the diagnostic picture is muddy, when AL amyloid hasn't been cleanly excluded, or when the response to first-line therapy is not what was expected, a second opinion at a high-volume center can clarify the path. In Southern California we have several academic centers with established amyloid programs, and the threshold to send a patient for a one-time consultation should be low.
Common Misconceptions
"Amyloid is rare, so it probably isn't me." Wild-type ATTR was thought to be rare because we couldn't diagnose it without a biopsy, and biopsies didn't get done. With the PYP scan we now find it in roughly one in seven older patients with HFpEF. It is not rare. It was hidden.
"My ejection fraction is normal, so my heart is fine." Ejection fraction tells you how forcefully the heart squeezes. It says little about how well the heart relaxes and fills. Stiff hearts with normal ejection fraction can produce severe symptoms and meaningful disease. ATTR amyloid is one of the classic causes.
"I'm too old to treat." Tafamidis and acoramidis have been prescribed in patients in their eighties and nineties. Age alone doesn't take treatment off the table. Functional status, life expectancy from other conditions, and your own goals all factor in.
"My carpal tunnel surgery was years ago and unrelated." The connection runs through a protein that has been depositing in your tissues for decades. The wrist, the spine, and the heart are all downstream of the same problem.
"If I have ATTR, my children will too." Wild-type ATTR is not inherited. Hereditary ATTR is, and gene testing tells the difference. About 90 percent of older adults with ATTR cardiac amyloidosis have the wild-type form, and family members do not need genetic testing.
"I can't afford the medication, so what's the point of diagnosis?" Patient assistance programs cover a substantial portion of patients on tafamidis and acoramidis. Knowing the diagnosis also changes how we manage your heart failure, atrial fibrillation, and aortic valve disease, which all benefit from clarity whether the drug is started right away or later.
Frequently Asked Questions
How long does it take to get diagnosed once you suspect amyloid?
In a focused workup, the AL labs, the PYP scan, and a genetic test can be lined up within two to four weeks. The bottleneck is often scheduling the nuclear scan and getting prior authorization. If the labs come back clean and the PYP is strongly positive, you can have a confirmed diagnosis at the four to six week mark from the first suspicion.
Is the PYP scan covered by insurance?
In most cases yes. Medicare covers it for the workup of suspected cardiac amyloidosis, and commercial insurers usually follow suit when the clinical picture supports the indication. Out-of-pocket costs vary, and the scan costs a fraction of what a heart biopsy would run.
Will tafamidis or acoramidis make me feel better?
Honestly, most patients don't notice a dramatic symptomatic shift on these drugs. They aren't quick relief medications. What they do is slow the disease. Patients on treatment have fewer hospitalizations and live longer than patients on placebo over a multi-year horizon. Diuretics and rate control are what make day-to-day symptoms better.
Can my heart disease be reversed?
Current treatments slow progression and stabilize the disease. They don't reverse the deposits already there. The realistic goal is to stabilize where you are and prevent further decline.
Do I need a heart biopsy?
In the right setting, no. If the AL amyloid blood and urine tests are clean and the PYP scan is strongly positive, the diagnosis of ATTR is confirmed without biopsy. Biopsy is reserved for patients with abnormal AL labs, an unclear PYP scan, or other features that don't fit cleanly.
My father had this. Should I get tested?
If your father had wild-type ATTR with a normal gene test, his disease is not inherited and routine testing of his children is not recommended. If he had hereditary ATTR with a TTR gene mutation, his children have a 50 percent chance of carrying the same mutation. Genetic counseling should be discussed in that case.
Will I need a pacemaker?
Some patients with ATTR cardiac amyloidosis develop slow conduction in the heart over time and end up needing a pacemaker. Not everyone does. Routine EKGs and ambulatory rhythm monitoring track this.
How does ATTR affect aortic stenosis treatment?
If you have severe aortic stenosis with co-existing ATTR amyloid, the valve still needs attention if symptoms warrant. TAVR is usually well tolerated. Recovery may be slower than in patients without amyloid, and the survival benefit from the valve procedure is real but smaller. Treating the amyloid alongside addressing the valve gives the best chance of a good outcome.
Should I exercise?
Yes, within limits set by your symptoms. Walking, light cycling, and moderate-intensity activity you can sustain without severe breathlessness are all reasonable. Heavy resistance training and high-intensity intervals are usually too much for an amyloid heart. A cardiac rehab program tuned to a stiff heart and low blood pressure is a useful starting point.
Is there anything dietary I should know?
Salt restriction matters more here than in many other heart conditions. The stiff amyloid heart fills poorly, and a salty meal that drives a few pounds of fluid retention will produce far more symptoms than the same meal in a non-amyloid heart. Most of my amyloid patients aim for under 2,000 milligrams of sodium a day.
References
1. Maurer, Mathew S., Jeffrey H. Schwartz, Balarama Gundapaneni, Perry M. Elliott, Giampaolo Merlini, Marcia Waddington-Cruz, Arnt V. Kristen, et al. "Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy." New England Journal of Medicine 379, no. 11 (2018): 1007-1016.
2. Gillmore, Julian D., Mathew S. Maurer, Daniel P. Judge, Pablo Garcia-Pavia, Sabahat Bokhari, Marianna Fontana, Brian M. Drachman, et al. "Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy." New England Journal of Medicine 390, no. 2 (2024): 132-142.
3. Kittleson, Michelle M., Frederick L. Ruberg, Amrut V. Ambardekar, Thomas H. Brannagan, Richard K. Cheng, John O. Clarke, Laura M. Dember, et al. "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis." Journal of the American College of Cardiology 81, no. 11 (2023): 1076-1126.
4. Gonzalez-Lopez, Esther, Mar Gallego-Delgado, Gonzalo Guzzo-Merello, Fernando Jose de Haro-del Moral, Marcos Cobo-Marcos, Carolina Robles, Belen Bornstein, et al. "Wild-Type Transthyretin Amyloidosis as a Cause of Heart Failure with Preserved Ejection Fraction." European Heart Journal 36, no. 38 (2015): 2585-2594.
5. Castano, Adam, Brian H. Narotsky, Nadia Hamid, Omar K. Khalique, Stephanie Morgenstern, Isaac DeLuca, Jose Rubin, et al. "Unveiling Transthyretin Cardiac Amyloidosis and Its Predictors Among Elderly Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement." European Heart Journal 38, no. 38 (2017): 2879-2887.
6. Sperry, Brett W., Adriana Reyes-Castro, Akshay Reddy, Wael A. Jaber, Mazen Hanna, Patrick Collier, Christine L. Jellis, et al. "Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release." Journal of the American College of Cardiology 72, no. 17 (2018): 2040-2050.
7. Witteles, Ronald M., Patricia Bokhari, Thibaud Damy, Perry M. Elliott, Rodney H. Falk, Martha Grogan, Brian Hummel, et al. "Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice." JACC: Heart Failure 7, no. 8 (2019): 709-716.
8. Adams, David, Alejandra Gonzalez-Duarte, William D. O'Riordan, Chih-Chao Yang, Mitsuharu Ueda, Arnt V. Kristen, Ivailo Tournev, et al. "Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis." New England Journal of Medicine 379, no. 1 (2018): 11-21.
9. Adams, David, Marcia Waddington-Cruz, Hartmut H. Schmidt, John L. Berk, Alejandra Gonzalez-Duarte, Teresa Coelho, Yoshiki Sekijima, et al. "Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy." New England Journal of Medicine 391, no. 16 (2024): 1467-1478.
10. Arbelo, Elena, Alexandros Protonotarios, Juan R. Gimeno, Eloisa Arbustini, Roberto Barriales-Villa, Cristina Basso, Connie R. Bezzina, et al. "2023 ESC Guidelines for the Management of Cardiomyopathies." European Heart Journal 44, no. 37 (2023): 3503-3626.
11. Kyle, Robert A., Angela Dispenzieri, Shaji K. Kumar, Morie A. Gertz, Vincent Rajkumar, Thomas E. Witzig, Suzanne R. Hayman, et al. "AL Amyloidosis: From Diagnosis to Prognosis and Beyond." Mayo Clinic Proceedings 97, no. 9 (2022): 1652-1668.
12. Ruberg, Frederick L., Mathew S. Maurer, Sharmila Dorbala, Jose Nativi-Nicolau, Edward J. Miller, Brett W. Sperry, Brian H. Annex, et al. "Prospective Evaluation of the Morbidity and Mortality of Wild-Type and V122I Mutant Transthyretin Amyloid Cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)." American Heart Journal 164, no. 2 (2012): 222-228.
Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.